In the course of cancer therapy, specialists have noticed a significant increase in fungal infections in oncology patients over the last two decades.

This is due to the greater number of patients whose condition is conducive to this type of infection, which means that more elderly patients, patients with diabetes, AIDS, post-transplant patients and those on immunosuppressive therapy are receiving oncological treatment.

The group potentially and practically susceptible to fungal infections is therefore increasing. The most common cause of systemic fungal infections is Candida group strains and, according to forecasts, there will be a further increase in the number of patients who contract fungal infections. Such infections, most commonly associated with the respiratory system, however, infection of another system (for example, urinary, gastrointestinal or nervous) or infection with another strain cannot be excluded. [1]